Researchers from the Australian Murdoch Childrens Research Institute have successfully trialled a treatment for peanut allergies that could potentially provide a long term cure for allergy sufferers.
Over 60 peanut allergic children were either given a dose of a probiotic, Lactobacillus rhamnosus, together with peanut protein in increasing amounts, or a placebo over 18 months to assess whether children would become tolerant to peanut.
The probiotic was a fixed daily dose, while the peanut oral immunotherapy was a daily dose of peanut protein starting at very low doses followed by a dose increase every two weeks until the maintenance dose (2g peanut protein) was reached. At the end of the treatment, the child’s ability to tolerate peanut was assessed by a peanut challenge performed two to five weeks after stopping treatment.
Astoundingly, researchers found over 80% of children who received the oral immunotherapy treatment were able to tolerate peanut at the end of the trial, compared to less than 4% of the placebo group. This is 20 times higher than the natural rate of resolution for peanut allergy.
23 of 28 (82.1%) probiotic treated children and one of 28 (3.6%) placebo-treated children were able to include peanut in their diet at the end of the trial. The likelihood of success was high – if nine children were given probiotic and peanut therapy, seven would benefit.
Lead researcher, Professor Mimi Tang said the study results are extremely exciting as they could potentially provide an effective treatment for food allergy.
“In the study the combined delivery of probiotic and oral immunotherapy was a safe and effective treatment for peanut allergy; however it is important to point out that this treatment must be only be given under close medical supervision as we are giving peanut to children who are allergic to peanut, and children did have allergic reactions. Nevertheless, the likelihood of success was high – if nine children were given probiotic and peanut therapy, seven would benefit.”
“It appears that we have been able to modify the allergic response to peanut such that the immune system produces protective responses rather than a harmful response to the peanut protein.”
The need for a curative treatment is greatest for peanut allergy since this is usually lifelong, and is the most common cause of fatality due to food induced anaphylaxis.
Further research is now required to confirm whether patients can still tolerate peanut years after the study has finished.
For more information, visit Murdoch Childrens Research Institute at www.mcri.edu.au